EMA published first summary of a risk-management plan for a medicine

EMA keeps  increasing  transparency and public access to relevant information on medicines. 

In february 2014 the first summary for the public of the risk-management plan (RMP) of a newly authorised medicine was published. The RMP summary  says what is known and not known about the medicine’s safety and what measures will be taken to prevent or minimise its risks.  This first public RMP summary concerns the drug Neuraceq.

Original source


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration